Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT03001622 ·Status: COMPLETED ·Phase: PHASE2

Bronchial Inflammation in Patients With Severe Immune Deficiency Under Immunoglobulin Treatment

NCT01359384 ·Status: UNKNOWN

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

NCT06339177 ·Status: RECRUITING

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH

NCT03985423 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

NCT02318082 ·Status: COMPLETED ·Phase: PHASE1

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

NCT00634569 ·Status: COMPLETED ·Phase: PHASE4

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

NCT01818492 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

NCT02082353 ·Status: UNKNOWN

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341 ·Status: COMPLETED ·Phase: PHASE3

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

NCT01175213 ·Status: COMPLETED ·Phase: PHASE3

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042 ·Status: TERMINATED ·Phase: PHASE4

Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

NCT00719680 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

NCT00023192 ·Status: COMPLETED ·Phase: PHASE3

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

NCT00072592 ·Status: COMPLETED ·Phase: PHASE1

An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

NCT05192200 ·Status: COMPLETED ·Phase: PHASE2

Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

NCT00417573 ·Status: COMPLETED ·Phase: PHASE2

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

NCT01485796 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT02783482 ·Status: COMPLETED ·Phase: PHASE3

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

NCT00001765 ·Status: COMPLETED ·Phase: PHASE1

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

NCT07123038 ·Status: RECRUITING

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations

NCT04641442 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease

NCT01211977 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Study of Belimumab Administered Subcutaneously to Healthy Subjects

NCT01583530 ·Status: COMPLETED ·Phase: PHASE1

Safety and Clinical Activity of Itolizumab in aGVHD

NCT05823675 ·Status: UNKNOWN ·Phase: PHASE1